Altered bioavailability due to changes in the formulation of a commercial preparation of levothyroxine in patients with differentiated thyroid carcinoma

Clinical Endocrinology

Volumn 46, Issue 6, 1997, Pages 707-711

  Olveira, G ^a   Almaraz, M C ^a   Soriguer, F ^a,b   Garriga, M J ^a   Gonzalez Romero, S ^a   Tinahones, F ^a   Ruiz De Adana, M S ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXNON; LEVOTHYROXINE SODIUM; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HORMONE INHIBITION; HUMAN; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THYROID CARCINOMA; THYROTROPIN RELEASE;

EID: 0030788224     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1997.1961006.x     Document Type: Article

References (23)

1. Barquero, M.J., Leyva, L., Garriga, M.J., López-Siguero, J.P. & Perán, S. (1996) Evaluación de los controles de tratamiento de hipotiroidismo tras un aumento generalizado de los valores de TSH. Endocrinología, 43, (Suppl. 1), 88.
2. Berg, J.A. & Mayor, G.H. (1993) A study in normal human volunteers to compare the rate and extent of levothyroxine absorption from Synthroid® and Levoxine®. Journal of Clinical Pharmacology, 33, 1135-1140.
3. Braverman, L.E. (1995) Levothyroxine: brand yes, generic no. Journal of Clinical Endocrinology and Metabolism, 80, 2876-2877.
4. Burrow, G.N. (1995) The thyroid: nodules and neoplasia. In Endocrinology and Metabolism (eds P. Felig, J.D. Baxter & L.A. Frohman), pp. 521-533. McGraw-Hill, New York.
5. Copeland, P.M. (1995) Two cases of therapeutic failure associated with levothyroxine brand interchange. Annals of Pharmacotherapy, 29, 482-485.
6. EFE (1996) Sanidad retira un fármaco para disfunciones en el tiroides. El País 11 May, 86.
7. Escalada, J., Ortego, J. & Sánchez-Franco, F. (1994) L-Tiroxina sódica: variaciones en el contenido hormonal de tres preparados comerciales diferentes. Endocrinología, 41, 13-16.
8. Escalante, D.A., Arem, N. & Arem, R. (1995) Assessment of interchangeability of two brands of levothyroxine preparations with a third-generation TSH assay. American Journal of Medicine, 98, 374-378.
9. Fish, L.H., Schwartz, H.L., Cavanaugh, J., Steffes, M.W., Bantle, J.P. & Oppenheimer, J.H. (1987) Replacement dose, metabolism and bioavailability of levothyroxine in the treatment of hypothyroidism. New England Journal of Medicine, 316, 764-770.
10. Hennessey, M.J., Burman, C.K. & Wartofsky, L. (1985) The equivalency of two L-thyroxine preparations. Annals of Internal Medicine, 102, 770-773.
11. Hennessey, M.J., Evaul, J.E., Tseng, Y., Burman, C.K. & Wartofsky, L. (1986) L-Thyroxine dosage: a reevaluation of therapy with contemporary preparations. Annals of Internal Medicine, 105, 11-15.
12. Liel, Y., Harman-Boehm, I. & Shany, S. (1996) Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. Journal of Clinical Endocrinology and Metabolism, 80, 857-859.
13. Madrid (1996) Enfermos de tiroides denuncian que no se les informó del cambio de su fármaco. El Mundo 12 May, 93.
14. Mazzaferri, E.L. & Young, R.L. (1981) Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. American Journal of Medicine, 70, 511-518.
15. Perán, S., Garriga, M.J., López-Siguero, J.P. & Peña, M. (1997) Valores elevados de TSH en los controles de tratamiento del hipotiroidismo congénito. Anales Espanoles de Pediatria 46, 167-171.
16. Perán, S., Garriga, M.J., Muñoz, M. & Clavero, A. (1992) Coste-efectividad en las pruebas bioquímicas de función tiroidea. Endocrinología, 39, 45-49.
17. Ramos-Gabatin, A., Jacobson, J.M. & Young, R.L. (1982) In vivo comparison of levothyroxine preparations. JAMA, 247, 203-205.
18. Rees-Jones, R.W., Rolla, A.R. & Larsen, P.R. (1980) Hormonal content of thyroid replacement preparations. JAMA, 243, 249-250.
19. Rhone-Poulenc, Rorer, S.A. (1996) Informa (announcement). El Pais 8 June, 64.
20. Sawin, C.T., Surks, M.I., London, M., Ranganathan, C. & Larsen, R. (1984) Oral thyroxine: variation in biologic action and tablet content. Annals of Internal Medicine, 100, 641-645.
21. Singer, P.A., Cooper, D.S., Levy, E.G., Ladenson, P.W., Braverman, L.E., Daniels, G., Greenspan, F.S., McDougall, R. & Nikolai, T.F. (1995) Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA, 273, 808-812.
22. Staub, J.J., Althaus, B.U., Engler, H., Ryff, A., Trabucco, P., Marquardt, K., Burckhardt, D., Girard, J. & Weintraub, B.D. (1992) Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. American Journal of Medicine, 92, 631-642.
23. Surks, M.I. & Sievert, R. (1995) Drugs and thyroid function. New England Journal of Medicine, 333, 1688-1694.